Harrow Health, Inc. (HROW)

NASDAQ: HROW · IEX Real-Time Price · USD
8.56
+0.12 (1.42%)
Aug 19, 2022 4:00 PM EDT - Market closed

Company Description

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation.

The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.

Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018.

Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Harrow Health, Inc.
Harrow Health Logo
Country United States
Founded 1998
Industry Pharmaceuticals
Sector Health Care
Employees 182

Contact Details

Address:
102 Woodmont Boulevard
Nashville, TN 37205
United States
Phone 615 733 4730
Website harrowinc.com

Stock Details

Ticker Symbol HROW
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 0001360214
CUSIP Number 415858109
ISIN Number US4158581094
Employer ID 45-0567010
SIC Code 2834

Key Executives

Name Position
Mark L. Baum J.D. Chief Executive Officer and Chairman
Andrew R. Boll C.F.A., C.M.A., CFA, CMA Chief Financial Officer and Corporate Secretary
Dr. Robert J. Kammer D.D.S. Special Advisor
John P. Saharek President of ImprimisRx
David Moufarrège Vice President of Technology
Jamie Webb Director of Communications and Investor Relations
Dr. Dennis E Saadeh Pharm.D. Chief of Formulation Strategy
Dr. Larry M. Dillaha Chief Medical Officer
Andrew Livingston Chief Innovation Officer

Latest SEC Filings

Date Type Title
Aug 9, 2022 10-Q Quarterly Report
Aug 9, 2022 8-K Current Report
Jun 13, 2022 8-K Current Report
Jun 6, 2022 EFFECT Notice of Effectiveness
May 26, 2022 S-3 Registration statement under Securities Act of 1933
May 5, 2022 10-Q Quarterly Report
May 5, 2022 8-K Current Report
Apr 26, 2022 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 26, 2022 DEF 14A Other definitive proxy statements
Apr 13, 2022 8-K Current Report